American Oriental Bioengineering (AOB) Gets Approval for New Products in Hong Kong
Tweet
Share
E-mailGet Alerts AOB Hot Sheet
Join SI Premium – FREE
American Oriental Bioengineering, Inc. (NYSE: AOB) reports that its Zhibai Dihuang Pill and Ciwujia Tablet have been approved for sale as traditional Chinese medicine in Hong Kong by Chinese Medicine Council of Hong Kong.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- enVVeno Medical (NVNO) files $100M mixed shelf
- Nu Skin EVP of global sales takes medical leave
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
